Hook & thesis
AeroVironment has been treated like a fallen growth darling: peak euphoria at $417 in 2025, then a painful re-price after program disruptions and litigation. That pendulum swing created an entry opportunity for tactical longs who believe the market has over-discounted AeroVironment's product moat and defense-market tailwinds.
Thesis in two lines: buy AVAV at or near $169 with a 180-trading-day horizon because the company retains differentiated small-UAS and loitering-munition offerings in an expanding $40B+ military drone market; downside is definable and tradable with a $150 stop while upside to $240 is attainable if contract cadence, manufacturing stability, and demand normalize.
Why the market should care
AeroVironment builds mission-critical platforms used for intelligence, surveillance and reconnaissance (ISR), electronic warfare, loitering munitions and counter-UAS - capabilities that are increasingly prioritized in defense budgets. Industry forecasts point to meaningful growth: military drone market projections see expansion from roughly $16.5B in 2025 to $42.8B by 2035. For a focused supplier with an established customer list and a national manufacturing footprint, that end-market tailwind matters.
Business snapshot and recent performance
At the current price of $168.87, AeroVironment's market capitalization is about $9.1 billion. Per the public metrics, book and profitability cues are mixed: trailing earnings per share are negative at -$5.24 and free cash flow was negative at -$140.9 million recently. At the same time, valuation multiples look stretched on an EV/EBITDA basis (around 45.7x), reflecting the selling of earnings visibility after program disruptions.
Important price context: AVAV swung from a 52-week high of $417.86 (10/09/2025) to a 52-week low of $135.20 (06/25/2026) and has since stabilized in the $160-180 area. Technicals show a near-term constructive tone: 10-day and 20-day SMAs sit at $155.40 and $150.34 respectively, and the RSI is ~57.6, consistent with upside momentum rather than an oversold bounce. Short interest has been nontrivial historically (millions of shares) but days-to-cover recently are low (~1.8), which reduces the risk of a violent short-squeeze reversal on its own.
Valuation framing
| Metric | Value |
|---|---|
| Current price | $168.87 |
| Market cap | $9.1B |
| EPS (trailing) | -$5.24 |
| EV/EBITDA | 45.7x |
| Free cash flow (recent) | -$140.95M |
Qualitatively, AVAV's current valuation is a market-implied bet that the company will return to growth and conversion of R&D investment into profitable contracts. The multiple is high given negative EPS, but it should be read as a forward-looking premium for defense-relevant IP and program optionality rather than a multiple on normalized earnings today. Compare this to the historical story: investors priced in scarcity of capability in 2025; today's price discounts program risk and litigation overhang.
Catalysts to drive upside (2-5)
- Contract renewals or new awards: visible wins on programs tied to loitering munitions, SCAR/SCN derivatives, or counter-UAS work would re-rate sentiment.
- Manufacturing stability and ramp: evidence of consistent delivery cadence from the national manufacturing footprint would improve revenue visibility and cash flow trajectory.
- Quarterly guidance and margin improvement: any trend showing shrinking FCF losses and a path toward positive operating cash would materially reduce the EV/EBITDA premium.
- Positive industry momentum: rising defense spending and the projected expansion of the military drone market to ~$42.8B by 2035 supports multiple expansion for winners.
Trade plan (actionable)
Entry: Buy at $169.02 (exact).
Target: $240.00 (exact) over a long term (180 trading days) - this assumes meaningful contract or margin news and partial recovery toward a normalized multiple once earnings clarity improves.
Stop loss: $150.00 (exact) - below the consolidation zone and well above the 52-week low; a break below $150 would indicate the market is re-pricing deeper fundamental issues.
Why 180 trading days? Defense procurements and program validations are inherently multi-quarter events. A 180-trading-day horizon gives time for bidding cycles, contract awards, manufacturing ramps, and sequential quarterly results that clarify FCF and margin trends.
Position sizing & risk control
This is a high-risk trade. Consider sizing so that a full stop loss hit implies no more than 1-2% of portfolio capital lost on this single idea. Revisit position if the stock trades above $200 with improving volume and confirmed contract news; consider trimming into strength rather than waiting for the whole run.
Supporting technical picture
Short-term technicals are constructive: price sits above the 10/20-day SMAs, MACD is in bullish momentum, and RSI is neutral-to-constructive. Volume patterns in late July showed elevated short-volume but average daily volume remains elevated versus seasonal norms, suggesting liquidity exists for planned entry and exits.
Risks and counterarguments
- Program execution risk: the stock fell after a stop-work and contract termination sequence earlier in the year; further contract cancellations or additional government diversification away from single vendors could meaningfully reduce revenue and margins.
- Litigation and disclosure risk: multiple law firms filed investigations and class actions in July/August 2026 alleging disclosure issues. Litigation can be costly, distracting, and may suppress the share price for extended periods.
- Cash burn and profitability: the company reported negative free cash flow (~-$140.9M) and negative EPS (-$5.24). If cash burn continues without a clear path to positive FCF or profitable scale, dilution or balance-sheet measures could compress returns.
- Competition and commercialization risk: the Space Force and other customers have signaled willingness to diversify suppliers and use COTS (commercial off-the-shelf) solutions. That could cap pricing power and reduce AVAV's contract share in some programs.
- Macro/defense budget risk: while defense budgets are generally supportive, political shifts or reprioritization could delay awards and procurement, reducing near-term revenues.
Counterargument
One plausible bear case is that AeroVironment never fully regains the program share it lost, and recurring litigation and program scrutiny elongate recovery. That would push valuation down and could make a $150 stop insufficient. However, the company’s focused portfolio in small UAS and proven manufacturing footprint still gives it structural advantages that competitors would need time and capital to replicate. Our trade assumes that at least some program reinstatement or new, smaller awards occur within 180 trading days — if that fails to materialize, the thesis weakens materially.
What would change my mind
I would materially reduce my target or flip to neutral/short if any of the following occur: a) new government findings that significantly degrade AVAV's eligibility for key programs; b) a second consecutive quarter of widening free-cash-flow losses without a credible financing plan; or c) sustained deterioration in backlog/visible orders. Conversely, a meaningful contract win with firm delivery dates or a quarter showing positive operating cash flow would strengthen the bull case and likely justify a higher target.
Conclusion
AeroVironment is not a low-risk, turn-around story — it is a high-risk, high-asymmetry trade. At $169.02 entry, clear downside can be capped with a $150 stop while upside to $240 over 180 trading days is realistic if program execution and contract flows improve. For investors willing to tolerate litigation and program noise, AVAV offers a tradeable contrarian opportunity into a secularly growing market for military drones and counter-UAS systems.
Trade idea: Buy AVAV at $169.02, target $240.00, stop $150.00. Time horizon: long term (180 trading days).